<DOC>
	<DOC>NCT00398294</DOC>
	<brief_summary>To collect lipid-lowering response data with the use of simvastatin 40 mg tablet in patients with hypercholesterolemia.</brief_summary>
	<brief_title>To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Male or female patient, &gt;18 years of age Patients with hypercholesterolemia who meet the following lipid criteria: 1. primary cholesterolemia: total cholesterol&gt;=240 mg/dl or ldlc &gt;= 160 mg/dl 2. secondary cholesterolemia (patients with cad, dm): ldlc&gt;=130 mg/dl The patient is willing to follow an NCEP therapeutic lifestyle changes (tlc) or similar cholesterollowering diet throughout the duration of the study Congestive heart failure (NYHA class III or IV), uncontrolled cardiac arrhythmias, unstable angina pectoris Myocardial infarction, coronary artery bypass surgery, or angioplasty within 3 months of visit 1 Uncontrolled hypertension with systolic blood pressure &gt; 160 mmhg or diastolic &gt; 100 mmhg at visit 1. Unstable diabetes (hba1c &gt;9%) or newly diagnosed (within 3 months)or change in antidiabetes medications within 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>